Previous 10 | Next 10 |
- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences: Piper Sandler 34 th Annual Healthcare Conference December 1, 2022 New York, New York 41 st Annual J....
Second of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO ® (filgrastim-ayow), a biosimilar referenci...
The US FDA has accepted Amneal Pharmaceuticals' ( NYSE: AMRX ) NDA for IPX203 (carbidopa/levodopa) for Parkinson's disease. The agency has provided an action date of June 30, 2023. IPX203 is novel, oral formulation of extended-release carbidopa/levodopa. Phase ...
- IPX203 could offer people living with Parkinson’s disease a longer duration of symptom control with less frequent dosing compared to IR CD/LD treatment - The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 30, 2023. Amneal Pharmaceuticals, Inc...
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Conference Call November 04, 2022, 08:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Anastasios Konidaris - Executiv...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q3 Non-GAAP EPS of $0.14 misses by $0.04 . Revenue of $545.56M (+3.2% Y/Y) misses by $16.61M . Reaffirms FY2022 Guidance : Reaffirms Net revenue to $2.15B-$2.25B vs. consensus of $2.20B; Adj EPS from pr...
‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook ‒ ...
Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Friday, November 4th, before market open. The consensus EPS Estimate is $0.18 (-14.3% Y/Y) and the consensus Revenue Estimate is $562.17M (+6.3% Y/Y). Over the last 2 years, AMRX ha...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...